Compare Stocks

Alsea, S.A.B. de C.V. operates restaurants in Latin America and Europe. It operates fast food, coffee shops, casual food, and family restaurants under the Domino's Pizza, Starbucks, Burger King, Chili's, PF Chang's, Italianni's, The Cheesecake Factory, Vips, The gate, Foster's Hollywood, Archies, Ginos, T.G.I. Fridays, Vips Europe, Vips Smart, Ole Mole, and Clay Hear brands. The company was incorporated in 1997 and is headquartered in Mexico City, Mexico.

Autogrill S.p.A., through its subsidiaries, provides food and beverage services for travelers in North America, Italy, and other European countries. It also sells fuel. The company operates through concessions at airports, motorway rest stops, and railway stations; and in shopping centers, trade fairs, and cultural attractions, as well as on high streets. It manages a portfolio of approximately 300 brands directly or under license. The company was founded in 1947 and is headquartered in Rozzano, Italy. Autogrill S.p.A. is a subsidiary of Dufry AG.

Boston Pizza Royalties Income Fund operates as a limited purpose open-ended trust. The company, indirectly through Boston Pizza Royalties Limited Partnership, owns trade-marks used by Boston Pizza International Inc. It operates and franchises Boston Pizza restaurants. The company was founded in 1964 and is based in Richmond, Canada. Boston Pizza Royalties Income Fund operates as a subsidiary of James Treliving Holdings Ltd.

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.